No Data
Inhibikase Therapeutics Files for Secondary Offering of Common Stock
Inhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy Rating
Inhibikase Therapeutics Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After Reporting Worse-than-expected Q3 EPS Results Yesterday.
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5
Inhibikase Therapeutics GAAP EPS of -$0.65 Misses by $0.17
Inhibikase Therapeutics | 10-Q: Q3 2024 Earnings Report
No Data
No Data